DelveInsight’s “Familial Adenomatous Polyposis Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Familial Adenomatous Polyposis, historical and forecasted epidemiology as well as the Familial Adenomatous Polyposis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Familial Adenomatous Polyposis Overview
Familial adenomatous polyposis is an autosomal dominant inherited condition in which numerous adenomatous polyps form mainly in the epithelium of the large intestine. While these polyps start out benign, malignant transformation into colon cancer occurs when they are left untreated. Three variants are known to exist, Familial Adenomatous Polyposis and attenuated Familial Adenomatous Polyposis (originally called hereditary flat adenoma syndrome) are caused by APC gene defects on chromosome 5 while autosomal recessive FAP (or MUTYH-associated polyposis) is caused by defects in the MUTYH gene on chromosome 1. O
Familial Adenomatous Polyposis Epidemiological Insights
The incidence of the mutation is between 1 in 10,000 and 1 in 15,000 births. By age 35 years, 95% of individuals with FAP (>100 adenomas) have polyps. Without colectomy, colon cancer is virtually inevitable. The mean age of colon cancer in untreated individuals is 39 years (range 34–43 years).
Attenuated FAP arises when APC is defective but still somewhat functional. As a result, it retains part of its ability to suppress polyps. Therefore, attenuated FAP manifests as colorectal cancer unusually late (age 40–70, average=55), and typically with few, or at least far fewer polyps (typically 30), than the more usual version of FAP, at an age when FAP is no longer considered much of a likelihood or risk according to usual FAP epidemiology.
Learn how the market will evolve by 2032 @ Familial Adenomatous Polyposis Market Trends and Developments
The Report Covers the Familial Adenomatous Polyposis Epidemiology Segmented by –
Familial Adenomatous Polyposis prevalent cases
Familial Adenomatous Polyposis incident cases
Familial Adenomatous Polyposis Treatment cases
Familial Adenomatous Polyposis diagnosed cases
Familial Adenomatous Polyposis Market Outlook
The Familial Adenomatous Polyposis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Familial Adenomatous Polyposis market trends by analyzing the impact of current Familial Adenomatous Polyposis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the Familial Adenomatous Polyposis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Familial Adenomatous Polyposis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Familial Adenomatous Polyposis market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies Working in the Familial Adenomatous Polyposis Market Includes
Emtora Biosciences
Cancer Prevention Pharmaceuticals
SLA Pharma
And many others
Familial Adenomatous Polyposis Therapies Covered and Analyzed in the Report:
REC-4881
Eicosapentaenoic Acid
Eflornithine
And many others
Read more about the Key Companies and Emerging Therapies in the Familial Adenomatous Polyposis Market
Table of Contents
Key Insights
Familial Adenomatous Polyposis Introduction
Executive Summary of Familial Adenomatous Polyposis
Disease Background and Overview
Epidemiology and patient population
Familial Adenomatous Polyposis Emerging Therapies
Familial Adenomatous Polyposis Market Outlook
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn more about the detailed offering of the report @ Familial AdenomatousPolyposis Market Outlook
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services